The GLP 1 Gold Rush: What's at Stake for DIY Investors? The biotech sector has been abuzz with excitement over a new class of drugs that mimic the action of glucagon like peptide 1 (GLP 1) hormones.
These medications have taken the market by storm, drawing investors to capitalize on this trend. Two companies, Eli Lilly and Viking Therapeutics, are leading contenders in the GLP 1 space.
Recent breakthroughs have expanded the addressable markets for these drugs beyond just diabetes and weight management.